Purchase this article with an account.
Han Sang Park, Si Yeol Kim, Oh Woong Kwon, Yang Jae Kim; 3-year results of short-duration multiple-session subthreshold micropulse yellow laser (577-nm) for chronic central serous chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):6193. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To review 3-year results of subthreshold micropulse yellow laser (SMYL) by short-duration (20 ms) multiple-session method for treatment of chronic central serous chorioretinopathy (CSC).
A retrospective and interventional study was performed from July 2011 to October 2017 at Nune Eye Hospital. SMYL photocoagulation with 577 nm wavelength, 15% duty cycle, multiple-session and low power from 200 mW to 400 mW increased by 100 mW depending on the resolution of subretinal fluid at monthly follow-up, 20 ms duration instead of conventional duration (100-300 ms), were applied over the area of retinal pigment epithelium (RPE) leakage and all area of serous retinal detachment, including fovea. 27 eyes of 27 patients with chronic or chronic recurrent CSC over 3-year of follow-up were enrolled.
Mean age of patients was 45.1±8.6 years and mean follow-up period was 3.7±0.8 years. 22/27 eyes (81.5%) including 6 recurrent cases during follow-up period showed complete resolution of subretinal detachment at final follow-up, and only 5 eyes (15.5%) showed no or partial response to SMYL treatment. The baseline best-corrected visual acuity was 0.26±0.24 logarithm of the minimum angle of resolution (logMAR), which was improved to 0.08±0.15 logMAR at the 1 year (p=0.005) and 3 years (p=0.01) follow-up, and 0.08±0.14 logMAR (p=0.008) at final follow-up. Central macular thickness at baseline was 389.6±103.4 μm, which was changed to 197.2±40.0 μm (p<0.001) at 1 year follow-up, 196.4±40.2 μm(p<0.001)at 3 years follow-up, and 193.5±40.0 μm (p<0.001) at final follow-up. There were no definite adverse effects.
A short-duration multiple-session SMYL may be effective for the treatment of chronic and recurrent CSC during long-term follow-up.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only